Cargando…
High-flow nasal oxygen decrease mortality in patients with severe SARS-CoV-2 pneumonia? Issues and controversies
Autores principales: | Di Costanzo, Domenica, Mandal, Mohanchandra, Mazza, Mariano, Esquinas, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989663/ https://www.ncbi.nlm.nih.gov/pubmed/35432987 http://dx.doi.org/10.1016/j.amsu.2022.103543 |
Ejemplares similares
-
Respiratory rate index utility in high-flow nasal cannula oxygen therapy in COVID-19 pneumonia; what are the perfect boundaries?
por: Mazza, Mariano, et al.
Publicado: (2022) -
High-flow versus Venturi Mask Oxygen Therapy to Prevent Reintubation: A Matter of Time or Device?
por: Mandal, Mohanchandra, et al.
Publicado: (2022) -
High-flow nasal oxygen in severe COVID-19 pneumonia and tocilizumab
por: Mandal, M., et al.
Publicado: (2022) -
Comment on “Dynamic Assessment of the ROX Index as a Predictive Tool During High-flow Nasal Oxygen Therapy: Underpinning Facts”
por: Goswami, Aritra, et al.
Publicado: (2023) -
Poor Respiratory Health Following Relapsing SARS-CoV-2 Infection in Children with Cystic Fibrosis: Correspondence
por: Mandal, Mohanchandra, et al.
Publicado: (2022)